Sightera
Uses AI-driven drug discovery to identify therapeutic insights by studying extreme patient biology before selecting targets.
Overview
Sightera is a Belgian biotech applying AI to drug discovery with a workflow described as reversing the conventional process. Rather than starting with a target, the company focuses on learning from “extreme” patient biology first to surface therapeutic insights. The company sits at the intersection of biotech and AI healthcare, targeting drug discovery use cases where patient-derived biology can guide research direction. Sightera raised €3M ($3M) in an undisclosed round announced in July 2026, providing early funding for its approach.
Funding History
Reversing AI drug discovery: Belgian biotech Sightera raises €3M to learn from ‘extreme’ patient biology first
Frequently Asked Questions
- How much has Sightera raised in total?
- Sightera has raised a total of $3M across 1 funding round.
- What does Sightera do?
- Sightera is a Belgian biotech applying AI to drug discovery with a workflow described as reversing the conventional process. Rather than starting with a target, the company focuses on learning from “extreme” patient biology first to surface therapeutic insights. The company sits at the intersection of biotech and AI healthcare, targeting drug discovery use cases where patient-derived biology can guide research direction. Sightera raised €3M ($3M) in an undisclosed round announced in July 2026, providing early funding for its approach.
- Where is Sightera headquartered?
- Sightera is headquartered in Belgium.
Related Insights
A comprehensive analysis of Sage's funding history, investors, competitive position, and growth trajectory in the AI Healthcare space.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $35.9 billion raised across 95 deals, with 15 mega-rounds capturing 85.5% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.